Logo Cepheid
Maggiori informazioni
Località/Lingua

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

{{initials}}
Main Menu
Località/Lingua

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

Maggiori informazioni
Maggiori informazioni

Xpert® MTB/XDR

Order now
TB drug computer generated depiction.

Semplificazione dei test di farmaco sensibilità per la TB utilizzando una maggiore capacità di multiplex con la tecnologia GeneXpert® a 10 colori

L’esigenza

An ill woman listens to a physician.
  • In 2022, only 43% of the total estimated multidrug-resistant Tuberculosis (MDR-TB) incident cases were diagnosed and enrolled on treatment regimen1
  • Only 47% of the total notified MDR-TB cases were tested for resistance to fluoroquinolones1
  • Increase access to rapid and extended drug resistance profiling for all TB-positive cases to rule out MDR/pre-XDR^ TB2
1 World Health Organization Tuberculosis Report 2023--https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/tb-disease-burden/1-3-drug-resistant-tb. Accessed January 2024.
2 Global Plan to End TB, STOP TB Report- https://omnibook.com/api/export/1.0/dc664b3a-14b4-4cc0-8042-ea8f27e902a6/-1/0/pdf^ Pre-XDR: Pre-Extensive Drug Resistant TB
^ Pre-XDR: Pre-Extensive Drug Resistant TB

La soluzione

A male and a female researchers scanning cepheid test cartridges.
The Xpert MTB/XDR test enables rapid molecular DST. When combined with the frontline Xpert MTB/RIF Ultra test, it detects mutations associated with resistance to isoniazid (INH), fluoroquinolones (FLQ), second-line injectable drugs (SLIDs), and ethionamide (ETH) in a single test.
  • Fast time to result for molecular DST
  • Risultati in <90 minuti
  • Same easy-to-use process as the Xpert MTB/RIF Ultra test
  • Eseguibile sulle piattaforme GeneXpert® esistenti dotate di moduli a 10 colori

L’impatto

A smiling female doctor attends an elderly woman.
  • Upfront molecular DST for TB‑positive cases supports timely treatment planning
  • Helps supports expanded access to drug‑resistance testing for MDR and pre‑XDR TB.3
  • The Xpert MTB/XDR assay provides the capability to differentiate between high and low-level resistance to INH and FLQ, which which provides additional information that may support resistance interpretation alongside clinical findings.4
3 Adam Penn-Nicholson et al. 2022 https://www.medrxiv.org/content/10.1101/2021.05.06.21256505v1.full.pdf
4 L Saderi, et al. 2022 https://www.archbronconeumol.org/es-pdf-S0300289622004987

Per risultati migliori

Maggiori informazioni

Approfondimenti

Get More Insights
Powered by Translations.com GlobalLink Web SoftwarePowered by GlobalLink Web